BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 27590563)

  • 1. Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen.
    Hirata Y; Serizawa T; Shichijo S; Suzuki N; Sakitani K; Hayakawa Y; Yamada A; Koike K
    Int J Infect Dis; 2016 Oct; 51():66-69. PubMed ID: 27590563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
    Georgopoulos SD; Xirouchakis E; Martinez-Gonzalez B; Sgouras DN; Spiliadi C; Mentis AF; Laoudi F
    Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori.
    Adachi T; Matsui S; Watanabe T; Okamoto K; Okamoto A; Kono M; Yamada M; Nagai T; Komeda Y; Minaga K; Kamata K; Yamao K; Takenaka M; Asakuma Y; Sakurai T; Nishida N; Kashida H; Kudo M
    Oncology; 2017; 93 Suppl 1():15-19. PubMed ID: 29258111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan.
    Hirata Y; Ohmae T; Yanai A; Sakitani K; Hayakawa Y; Yoshida S; Sugimoto T; Mitsuno Y; Akanuma M; Yamaji Y; Ogura K; Maeda S; Koike K
    Int J Antimicrob Agents; 2012 Apr; 39(4):352-5. PubMed ID: 22321702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan.
    Sugimoto M; Sahara S; Ichikawa H; Kagami T; Ban H; Otsuka T; Andoh A; Furuta T
    Helicobacter; 2017 Feb; 22(1):. PubMed ID: 27213463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori.
    Hu TH; Chuah SK; Hsu PI; Wu DC; Tai WC; Chiu YC; Wu KL; Kuo CM; Hu ML
    Am J Med Sci; 2011 Sep; 342(3):177-81. PubMed ID: 21804375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
    Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation.
    Mori H; Suzuki H; Matsuzaki J; Tsugawa H; Fukuhara S; Miyoshi S; Hirata K; Seino T; Matsushita M; Masaoka T; Kanai T
    Helicobacter; 2016 Aug; 21(4):286-94. PubMed ID: 26612407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection.
    Puig I; González-Santiago JM; Molina-Infante J; Barrio J; Herranz MT; Algaba A; Castro M; Gisbert JP; Calvet X
    Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28869699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
    Sue S; Shibata W; Sasaki T; Kaneko H; Irie K; Kondo M; Maeda S
    J Gastroenterol Hepatol; 2019 Apr; 34(4):686-692. PubMed ID: 30151994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy.
    Mori H; Suzuki H; Matsuzaki J; Masaoka T; Kanai T
    Digestion; 2020; 101(5):644-650. PubMed ID: 31387107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin.
    Miehlke S; Schneider-Brachert W; Kirsch C; Morgner A; Madisch A; Kuhlisch E; Haferland C; Bästlein E; Jebens C; Zekorn C; Knoth H; Stolte M; Lehn N
    Helicobacter; 2008 Feb; 13(1):69-74. PubMed ID: 18205669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esomeprazole-based 1-week triple therapy directed by susceptibility testing for eradication of Helicobacter pylori infection in children.
    Arenz T; Antos D; Rüssmann H; Alberer M; Buderus S; Kappler M; Koletzko S
    J Pediatr Gastroenterol Nutr; 2006 Aug; 43(2):180-4. PubMed ID: 16877981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.
    Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Uotani T; Sahara S; Ichikawa H; Yamada T; Osawa S; Sugimoto K; Watanabe H; Umemura K
    J Gastroenterol Hepatol; 2014 Mar; 29(3):487-93. PubMed ID: 24224808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Helicobacter pylori cure rate with sitafloxacin-based triple therapy.
    Sugimoto M; Sahara S; Ichikawa H; Kagami T; Uotani T; Furuta T
    Aliment Pharmacol Ther; 2015 Aug; 42(4):477-83. PubMed ID: 26075959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.
    Tai WC; Liang CM; Kuo CM; Huang PY; Wu CK; Yang SC; Kuo YH; Lin MT; Lee CH; Hsu CN; Wu KL; Hu TH; Chuah SK
    J Antimicrob Chemother; 2019 Jun; 74(6):1718-1724. PubMed ID: 30768161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
    Nista EC; Candelli M; Zocco MA; Cremonini F; Ojetti V; Finizio R; Spada C; Cammarota G; Gasbarrini G; Gasbarrini A
    Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study.
    Kwon YH; Kim N; Lee JY; Choi YJ; Yoon K; Nam RH; Suh JH; Lee JW; Lee DH
    Scand J Gastroenterol; 2016 Mar; 51(3):270-6. PubMed ID: 26452405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.